Skip to main content
PLRX logo

PLRX · Pliant Therapeutics, Inc. · Executive Compensation

Track PLRX — free
$0.92 +0.01 (+0.83%)
Market Cap
$56.50M
Shares
61.92M
Volume · Oct 21 3256 Avg daily vol (3M) 421.65K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Bernard Coulie $5,462,901
Éric Lefebvre $2,724,860
Keith Cummings $2,397,337
Minnie Kuo $1,542,854
Fiscal 2024
Executive Total
Bernard Coulie $6,614,704
Keith Cummings $3,099,874
Éric Lefebvre $2,615,618
Hans Hull $2,015,324
Mike Ouimette $1,994,260
Fiscal 2023
Executive Total
Bernard Coulie $11,165,999
Éric Lefebvre $4,687,061
Keith Cummings $4,438,908
Hans Hull $4,357,277
Mike Ouimette $3,316,978
Fiscal 2022
Executive Total
Bernard Coulie $10,927,715
Éric Lefebvre $3,903,337
Keith Cummings $3,443,354
Hans Hull $3,154,751
Mike Ouimette $2,542,248
Fiscal 2021
Executive Total
Bernard Coulie $5,221,353
Éric Lefebvre $1,974,231
Keith Cummings $1,883,743
Hans Hull $1,653,630
Barbara Howes $995,913
Mike Ouimette $805,039
Fiscal 2020
Executive Total
Bernard Coulie $2,391,822
Éric Lefebvre $874,671
Hans Hull $839,867
Fiscal 2019
Executive Total
Bernard Coulie $2,372,486
Hans Hull $846,266

Executive changes

Person Change Filed
Flavia Borellini, Ph.D. Appointed 2026-07-13
Robert Iannone, M.D., M.S.C.E. Appointed 2026-07-13
Suzanne Bruhn Retired 2026-04-17
Katharine Knobil Retired 2026-04-17
David E.I. Pyott Retired 2026-04-17
Minnie Kuo Appointed 2025-12-16
Éric Lefebvre, M.D. Terminated 2025-12-08
Hans Hull Resigned 2025-10-24
Mike Ouimette Terminated 2025-05-01
Steve Krognes Appointed 2024-06-14
Steve Krognes Appointed 2024-06-14
Darren Cline Appointed 2023-03-08
Thomas McCourt Appointed 2023-03-08
Neil Exter, MBA Retired 2022-11-18
Neil Exter, MBA Retired 2022-11-18
Dr. Katharine Knobil Appointed 2022-09-16

Leadership

Key facts CIK 1746473 CUSIP 729139105 13F (30d) 2 filings 2 filers Visit website Investor relations